| Management target | Revenue 17.5% FY31 |
|---|
| Revenue growth | 23.7% YoY growth driven by volume and international operations mix. |
|---|---|
| Margins | Structural expansion to 23.1% aided by international revenue and procurement. |
| Demand visibility | Strong; 80% of Indian dialysis market remains unorganized and underserved. |
| Management confidence | Balanced and highly focused on repeatable platform-led execution. |
Growth
Revenue grew 23.7% YoY to ₹282 Cr; adjusted EBITDA grew 30.7% with 120bps margin expansion.
Outlook
Management maintains medium-term growth guidance of 15-20% over the next 3 to 5 years.
Risks
Structural high AR days (101 days) and potential for binary failure in lumpy Saudi tender markets.
Last quarter's promises, checked
Delivered
- Guided 15-20% revenue CAGR → delivered 32.2% FY26 growth (= BEAT)
- Targeted 40-50 India clinic additions → delivered 468 total clinics (net 21 additions) (= BEAT)
- Guided 10-15 Philippines clinic additions → delivered 44 total clinics (= BEAT)
Partly delivered
- Targeted Saudi Arabia operational launch → Riyadh clinic launch set for next 2 months (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: NEPHROPLUS. Summary written with AI assistance from the document.
Nephrocare Health Services Ltd: key numbers
- Share price
- ₹696.65
- Market cap
- ₹6,990 Cr
- Revenue (annual)
- ₹998.8 Cr
- Net profit (annual)
- ₹76.84 Cr
- P/E (TTM)
- 82.1×Sector 57.8×
- Promoter holding
- 63.85%+0.00% QoQ
- FII holding
- 8.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nephrocare Health Services Ltd
All →Nephrocare Health Services Credit Rating
India Ratings upgraded Nephrocare Health Services' long-term bank loan facilities to IND AA-/Stable. The agency also affirmed the company's short-term credit ratings.
Nephrocare Health Services Merger & Restructuring
Nephrocare Health Services Ltd announced the rationalisation and consolidation of its step-down subsidiaries in the Philippines. This internal reorganization streamlines the group's existing structure.
Nephrocare Health Services Merger & Restructuring Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary acquired a dialysis center from Renal One Dialysis Corp for ≈₹10.25 Cr. The asset transfer expands the company's dialysis network.
- Value
- ₹10.25 Cr
- dialysis center acquired
- 1 dialysis centers
Nephrocare Health Services Acquisition Worth ₹10.25 Cr
Nephrocare's Philippines subsidiary is acquiring a dialysis center from Renal One Dialysis Corp. for a consideration of ₹10.25 crore.
- Value
- ₹10.25 Cr
Nephrocare Health Services Employee Stock Options
Nephrocare Health Services granted 4,01,362 employee stock options at an exercise price of ₹230 per share. These options are issued under the NephroPlus Employee Stock Option Scheme 2026.
Nephrocare Health Services Investor Presentation: Key Takeaways
Nephrocare Health Services (NephroPlus) reported Q1FY27 revenue of ₹281.8 Cr, up 23.7% YoY. Strategy focuses on international scaling and high-margin organized dialysis network leadership.